Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044209 | 0.88 | HRH3 (0.43) | NPC1RAB9ASMN1; SMN2CNR1TSHR | |
| SCHEMBL4044491 | 0.87 | KMT2A (0.41) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4040060 | 0.87 | LMNA (0.48) | NPC1RAB9ACNR1CNR2TSHR | |
| SCHEMBL4038206 | 0.86 | NPC1 (0.43) | NPC1RAB9AMEN1GAAKMT2A | |
| SCHEMBL4038094 | 0.83 | TSHR (0.45) | MEN1KMT2ASMN1; SMN2CNR1CNR2 | |
| SCHEMBL4037604 | 0.83 | MDM2 (0.48) | MEN1KMT2ASMN1; SMN2CNR1CNR2 | |
| SCHEMBL4042732 | 0.82 | NR1H4 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4039101 | 0.82 | NR1H4 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4038040 | 0.81 | TSHR (0.38) | MEN1KMT2ASMN1; SMN2CNR1TSHR | |
| SCHEMBL4044540 | 0.80 | NR1H4 (0.44) | NPC1RAB9ASMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | claimed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | claimed |
| EP-3043865-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036442-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-03-19 | — | — | WO | disclosed |
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |